Hantavirus Vaccine in 2026: Odds & Probability
Markets currently price the chance of full FDA approval for a hantavirus vaccine by Jan 1, 2027 at 5.5%, a scenario the crowd views as unlikely.
Updated · Volume $131.7K
The Yes outcome is unlikely, while the No scenario captures the overwhelming balance of probability.
Context
The market's assessment currently registers 5.5%. To resolve Yes, a vaccine intended to inoculate humans against Hantavirus—including Hantavirus Pulmonary Syndrome or Hemorrhagic Fever with Renal Syndrome—must receive full approval from the U.S. Food and Drug Administration. The cutoff is Jan 1, 2027. If no such approval occurs by that deadline, the market settles to No. The FDA’s official list of licensed vaccines serves as the primary resolution source, although a consensus of credible reporting may also be used. Key drivers include formal regulatory milestones: the completion of successful Phase III trials, acceptance of a Biologics License Application, or a favorable advisory committee vote. Any news altering the perceived likelihood of a timely FDA nod could shift the odds. The hard stop is Jan 1, 2027, after which the market resolves. Because resolution relies on the FDA’s published approvals, ambiguity about whether a vaccine qualifies is minimal.
FAQ
What must happen for the market to resolve to Yes?
A hantavirus vaccine for human use must receive full approval from the U.S. FDA by the resolution deadline.
Does emergency use authorization count as approval?
No. The market specifically requires full FDA approval; emergency use authorization is not sufficient.
What happens if a vaccine is approved after the deadline?
The market would resolve to No, as the cutoff is strictly enforced.
How is the approval verified for resolution?
Resolution is based on the FDA’s official list of licensed vaccines. In its absence, a consensus of credible media reports may be used.
Which diseases does this market consider under hantavirus?
It includes both Hantavirus Pulmonary Syndrome (HPS) and Hemorrhagic Fever with Renal Syndrome (HFRS).
Data: Polymarket · Methodology · Not financial advice